Ignite Creation Date:
2024-05-11 @ 8:30 AM
Last Modification Date:
2024-10-26 @ 3:29 PM
Study NCT ID:
NCT06403709
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-05-08
First Post:
2024-04-01
Brief Title:
Irinotecan TAS-102 Plus Bevacizumab as a Third-Line or Beyond Therapy in mCRC Patients
Sponsor:
Cancer Institute and Hospital Chinese Academy of Medical Sciences
Organization:
Cancer Institute and Hospital Chinese Academy of Medical Sciences
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-08-01
Start Date Type:
ACTUAL
Primary Completion Date:
2024-08-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-08-01
Completion Date Type:
ESTIMATED
First Submit Date:
2024-04-01
First Submit QC Date:
May 4 2024
Study First Post Date:
2024-05-08
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-09-22
Last Update Post Date:
2024-05-08
Last Update Post Date Type:
ACTUAL